NCT00793975 - Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

IMC-1121B

"Cohort 1~2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

1121B

"Cohort 2~4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

1121B

"Cohort 3~6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

1121B

"Cohort 4~8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

1121B

"Cohort 5~10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

1121B

"Cohort 6~13 mg/kg once a week for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

1121B

"Cohort 7~16 mg/kg once a week for 4 weeks, followed by a 2-week observation period."

Trial Locations (2)

ImClone Investigational Site, Philadelphia

ImClone Investigational Site, Aurora

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY